Automating regenerative medicine for scalable autologous treatments.

A Lab-in-a-Box technology for tissue repair. Turning a small sample of a patient’s own tissue into a personalised topical preparation, inside the clinic.

  1. A gloved hand holding a vial of amber liquid
    Collect

    A small sample of the patient’s own tissue, easily collected in the clinic.

  2. Process

    100% automated preparation with a single-use proprietary consumable.

  3. A topical gel being applied to the skin of a forearm
    Apply

    A personalised preparation, applied to the skin

Proposed workflow as a representation of the treatment. Details are confidential. Device images are concept renderings; people shown are illustrative.

Great potential. Complex implementation.

The therapeutic efficacy of regenerative medicine is widely demonstrated. Bringing it into everyday clinical practice, however, presents three critical barriers:

  1. Manual preparation

    Hands-on processing requires significant clinician time, specialized training, and leads to protocol variability between clinics.

  2. Hard to standardise

    Without automated protocols, achieving consistent, repeatable formulations across multiple centers is difficult to scale.

  3. Injection-based delivery

    Traditional regenerative procedures rely heavily on injections, causing patient discomfort and limiting treatment adoption.

Portrait of a woman in her forties, looking to the side
Illustrative image.

From sample to skin, in the treatment room.

The Lab-in-a-Box is designed to take over the manual preparation, so a clinic can offer a personalised topical treatment from the patient’s own biology.

A gloved hand holding a vial of amber liquid Concept rendering of the REGEMED Lab-in-a-Box device A clinician applying a topical preparation to a patient’s cheek

A small sample of the patient’s own tissue.

A small tissue sample is collected in the clinic. The preparation is autologous, starting directly from the patient’s own biological material.

Collect

Automated preparation, one kit per patient.

The Lab-in-a-Box processes the sample automatically with a proprietary single-use kit. It is designed to reduce manual handling and keep every preparation consistent.

Process

A personalised topical preparation.

The preparation is applied to the skin, without an injection. The first focus is regenerative aesthetics in premium clinics.

Apply

Proposed workflow. Device images are concept renderings; people shown are illustrative. The device is not yet commercially available.

Current development stage

  1. Development stage

    Medical device development

    Building the proprietary Lab-in-a-Box hardware and standardized preparation protocols.

  2. Scientific validation

    Proof of concept with VHIR

    Planned research milestone in collaboration with Vall d’Hebron Research Institute (VHIR).

  3. Regulatory & certification

    IP protection strategy and regulatory path

    Development of the patent portfolio and definition of the regulatory path through to CE marking.

What is the regulatory status and EU MDR classification of the device?

This website presents technology currently in development and does not describe a product with CE certification. A preliminary regulatory assessment under EU MDR has been defined, and detailed regulatory pathways are shared confidentially with interested investors upon request.

What makes REGEMED’s technology different?

The bottleneck in regenerative medicine is not biological: it is logistical and regulatory. REGEMED is designed to decouple autologous preparation from centralized infrastructure, with compact hardware and closed, recurring consumables, so a clinic can offer autologous treatments without a large investment in its own infrastructure.

How does REGEMED protect its intellectual property?

Our technology, device architecture, and automated workflows are built around proprietary engineering and protected design strategies as we advance toward commercial deployment.

How is the hardware development being executed?

Device development is carried out in collaboration with a specialized externalized medical device engineering partner, ensuring industry-standard quality, ISO 13485 compliance, and efficient execution.

How can I learn more about the investment opportunity?

Contact the founders to request the investor deck and discuss the technology, the development plan, and the business model.

The intersection of two high-growth markets

€76bn ~16% CAGR Global non-invasive & tissue care market, 2025. Projected €137bn by 2032.

€51bn ~34% CAGR Global regenerative medicine market, 2025. Projected €413bn by 2032.

REGEMED targets specialized clinics seeking a standardized, automated workflow for personalized autologous tissue preparation.

Business model

Concept rendering of the REGEMED device beside its single-use consumable kit
Concept rendering.

A device in the clinic

The automated Lab-in-a-Box technology is placed directly in the treatment room, bringing point-of-care processing to the clinic.

A single-use kit per patient

Each preparation uses a proprietary, single-use processing kit, establishing a scalable recurring model aligned with clinic volume.

The people behind REGEMED

Medical and business leadership from day one, with leading scientific advisors.

Olau Cantero

Olau Cantero

Co-founder & CEO

Leads business and finance.

Write to Olau
Aleix Cuenca

Aleix Cuenca

Co-founder & CMO

Leads medical and regulatory affairs.

Write to Aleix

Advisory board

Scientific & clinical advisory

REGEMED is supported by specialists and experts in regenerative medicine, aging, and reconstructive surgery. Advisor credentials and clinical references are shared confidentially with verified investors.

Supported by a connected ecosystem

  • VHIRProof of Concept Partner
  • ENISACertified emerging company
  • CRAASH BarcelonaAcceleration programme
  • MicroBankFinancing
  • AMBGrant support
  • Horizon Deep Tech SummitTop 30 of 150+

Partner with REGEMED

Request the investor deck or schedule an introductory call with the founders. We will walk you through our technology, development roadmap, and investment opportunity.

Barcelona Health HubCarrer de Sant Antoni Maria Claret 167
08025 Barcelona, Spain